Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin

eNeuro
126 June 2021
https://pubmed.ncbi.nlm.nih.gov/34031099/

Integrated Review of the Assessment of Newborns With Neonatal Abstinence Syndrome

J Obstet Gynecol Neonatal Nurs
08 June 2021
https://pubmed.ncbi.nlm.nih.gov/34116058/

Objective: To critically review and summarize current knowledge regarding the assessment of newborns with neonatal abstinence syndrome (NAS).

Extended-release naltrexone for youth with opioid use disorder

J Subst Abuse Treat
15 April 2021
https://pubmed.ncbi.nlm.nih.gov/34118699/

Background: Few published research studies have examined the effectiveness of extended-release naltrexone (XR-NTX) for the treatment of opioid use disorder (OUD) among adolescents and young adults.

Complex Regional Pain Syndrome: A Comprehensive Review 

Pain Ther
24 June 2021
https://pubmed.ncbi.nlm.nih.gov/34165690/

Katie, LDN, Fibromyalgia, pain, fatigue and brain fog (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial

J Diabetes
20 May 2021
https://pubmed.ncbi.nlm.nih.gov/34014028/

Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients

Hum Psychopharmacol
24 May 2021
https://pubmed.ncbi.nlm.nih.gov/34029405/

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and Beta-Endorphin

eNeuro
24 May 2021
https://www.eneuro.org/content/early/2021/05/21/ENEURO.0087-21.2021